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Pregnancy and the postpartum period have an increased incidence of venous thromboembolism (VTE). The condition is unique
during this period for several reasons. Primarily, because there is complexity in diagnosing this condition in view of altered phys-
iologyandpreexistingedemainpregnancyandalsobecausetherearerestrictionsontheuseofcertaindrugsandaneedforvigilant
monitoring of anticoagulant activities of drugs during the period. The problem is compounded and assumes the highest order of
signiﬁcancesincetwolivesareinvolvedandalltheinvestigationsandmanagementdoneshouldalsotakeintoaccountthepotential
adverse eﬀects on the foetus. In order to prevent the development of VTE during pregnancy, sound clinical evaluation for risk
factors, risk stratiﬁcation, and optimal use of resource both mechanical and pharmacological is necessary. This paper details
strategies in preventing development of deep vein thrombosis and treatment of VTEs.
1.Introduction
Venousthromboembolismisusedtodenotetwodiseasecon-
ditions: deep vein thrombosis (DVT) and pulmonary em-
bolism(PE).Thetwoconditionsareinterrelatedinamanner
that approximately one third of all cases of isolated PE will
have DVT on diagnostic evaluation and similarly approxi-
matelyhalfthecasesofDVTofproximalveinsoflegwillhave
clinical silent or apparent PE [1–3]. VTE assumes a special
signiﬁcance during pregnancy due to its increased incidence,
diﬃculty in diagnosis, and complexities in management.
The incidence of VTE in pregnancy is approximately ﬁve
times the incidence in nonpregnant patients and is reported
to be 0.7 to 1.2 per 10000 pregnancies [4, 5]. This risk
increases to approximately 20 times in the postpartum
period. DVTconstitutesalmost80%ofcasesofVTE,andthe
rest are constituted by PE. It also accounts for 10% maternal
deathsinthewesternworldorroughly1.1deathsper100000
deliveries [6].
Virchow in 1856 suggested that development of PE could
be attributed to stasis, endothelial injury, and hypercoagula-
ble state [7]. Over the years, various research investigations
have upheld his observation. Pregnancy is classiﬁed as a hy-
percoagulable state as the ﬁbrin generation is increased,
ﬁbrinolytic activity is decreased, levels of coagulation factors
II, VII, VIII, and X are all increased, free protein S levels are
decreased, and acquired resistance to activated protein C is
commonly seen [8, 9]. During normal uncomplicated preg-
nancy, there is also an evidence of substantial haemostatic
activation as indicated by increased markers of coagulation
activation,suchasprothrombinfragmentF1+2andD-dimer
[9]. Also, there is hormonally induced decreased venous
capacitance and reduced venous outﬂow due to mechanical
obstruction from uterus [10, 11]. There is 50% decrease in
the venous outﬂow during 26–30 weeks of gestation which
continues through 6 weeks postgestation (Table 1).
Additional risk factors include the presence of inherited
thrombophilias and the antiphospholipid syndrome, previ-
ous history of thrombosis, black race, heart disease, sickle
cell disease, diabetes, lupus, smoking, multiple pregnancy,
age greater than 35 years, obesity, and caesarean delivery
(especially emergency caesarean section during labor) [12–
15]( Table 2).
2. Strategies for DiagnosingVTE
2.1. Risk Stratiﬁcation. It is vital that a high degree of sus-
picion and clinical vigilance be maintained during the2 Journal of Pregnancy
Table 1: Causes for increased incidence of VTE during pregnancy.
(1) Hypercoagulation state in pregnancy
(a) Increase in the levels of procoagulants
(i) Factor II, factor VII, factor X, and ﬁbrin
(2)Anticoagulants decrease
(a) Acquired protein C resistance
(b) Decreased levels of protein S
(3) Increased venous stasis
(a) Decreased venous capacitance under hormonal inﬂuence
(b) Increased intravascular volume distends veins
(c) Inferior vena cava obstructed secondary to pressure from uterus
(4) Vascular damage
(a) Related to vaginal and caesarean delivery
pregnancy and postpartum period. It is worth noting that
typical signs like leg swelling, tachycardia, tachypnea, and
dyspnoea that raise the suspicion of VTE in the nonpregnant
are often already present as a response to physiological
changes occurring during the pregnancy [16, 17]. All cases of
suspicion of VTE should be investigated expeditiously with
following available modalities.
2.2. Duplex Ultrasonography. The preferred modality for
investigation of DVT is duplex ultrasonography which has
a sensitivity of approximately 97% and speciﬁcity of approx-
imately 94% in general population for proximal venous
thromboembolism [18–20, 19]. It is usually done with a 5Hz
probe and incorporates two elements: gray-scale ultrasound
and colour Doppler study. Gray-scale ultrasound is used
to visualize the structure or the architecture of the body
part. Colour Doppler is used to visualize the ﬂow in the
vessel. Normal venous ﬂow produces a low pitched sound
that is absent in case of venous occlusion. The ultrasound
examination not only helps to determine the anatomy and
patency but also can be used to evaluate the augmentation
(increased ﬂow with calf compression) and compression
(elimination of the residual lumen by ﬁrm pressure of the
hand-held transducer probe).
Limitations of duplex ultrasound: duplex ultrasound is
not very eﬀective in diagnosing asymptomatic and calf vein
DVT with only a reported sensitivity of 36% of calf vein
VTE [21]. Similarly, for more proximal thrombus like those
involving the iliac veins, it may be necessary to perform an
MRIdirectthrombusimagingasitdoesnotinvolveradiation
and harmful eﬀects on the foetus [22].
2.3. D-Dimer. D-dimer is another test which when used
with other investigations may help in reaching conclusive
diagnosis although the D-dimer level is normally elevated
during the pregnancy [23, 24]. This hampers the use of
normal reference values [25]t or u l eo u tV T Eo rt om o n i t o r
antithrombotic treatment when used alone. However, when
used in conjunction with other modalities, it can help rule
out the condition when in doubt. Nishii et al. in a large
prospectivestudyshowedthatthetesthadpositive predictive
value of 7.4% and negative predictive value of 95.5% for
Table 2: Risk factor for development of VTE.
(1) Previous history of thrombosis
(2) Primary thrombophilia (e.g., factor V Leiden)
(3) Caesarean section delivery esp. emergency section during
labour
(4) Sickle cell disease
(5) Mechanical heart valve
(6) Smoking
(7) SLE
(8) Atrial ﬁbrillation
(9) Inﬂammatory bowel disease
(10) Nephrotic syndrome
(11) Antiphospholipid syndrome
(12) Prolonged immobilization (e.g., bed rest)
(13) Recent major surgery or trauma
(14) Age over 35 years
(15) Obesity (BMI > 30kg/m2)
(16) Multiparity over 4 deliveries
(17) Preeclampsia
(18) Current infection
(19) Complications of pregnancy such as antepartum or
postpartum hemorrhage, hyperemesis gravidarum, condition
requiring blood transfusion, and ﬂuid-electrolyte imbalance
ultrasonographically positive women when D-dimer was set
at 3.2microg/mL [26]. Table 3 below gives an indicative
range of D-dimer during pregnancy.
2.4. Diagnosing Pulmonary Embolism. In case of suspicion of
pulmonary embolism (PE), additional investigations need to
beperformed.AnX-rayofchesthelpstoexcludeothercauses
that lead to dyspnoea and tachycardia. Other investigations
of choice are ventilation-perfusion scan and CT pulmonary
angiography [27, 28]. Both these tests though routinely
used for diagnosing PE in normal population are used with
a caution in this group owing to the fact that their use
involves radiation exposure to both mother and foetus and
have been reported to be associated with increased incidence
of childhood cancers and maternal breast cancers.
2.5. Ventilation-Perfusion Scan. Ventilation-perfusion scan
usedtobethemorefrequentlyemployedmodality ofinvesti-
gation in these cases [29]. In pregnant women, the radiation
dose can be minimized by using a half-dose perfusion
scan and only proceeding to ventilation imaging once an
abnormal defect is obtained during the perfusion scan. This
test if negative can help conﬁdently exclude the presence of
PE; however, the test can indicate an indeterminate results in
large number of patients in this group with up to 20% who
have been shown to have high probability for the condition
not actually having PE.
2.6. CT Pulmonary Angiography (CTPA). CTPA has gradu-
ally taken over as the investigation of choice for investigating
the cases with suspicion of PE. This is due to the factJournal of Pregnancy 3
Table 3: Plasma D-dimer levels during pregnancy.
D-dimer (plasma)
Units Adult First
trimester
Second
trimester
Third
trimester
µg/mL <0.5 0.05–0.95 0.32–1.29 0.13–1.7
µg/L
ng/mL <500 50–950 320–1290 130–1700
nmol/L <2.7 0.3–5.2 1.8–7.1 0.7–9.3
that it has high sensitivity (around 94%), high speciﬁcity
(around 100%), and an excellent negative predictive value
of 99% [30, 31]. Unlike V/Q scan, in CTPA, the thrombus
can be directly visualised and other alternative cause for the
symptoms may also be detected. Another advantage of CTPA
over the V/Q scan is the fact that the radiation exposure in
CTPA is almost half that of those received during V/q scan.
In a typical CTPA, the radiation exposure to foetus is around
3.3uGyto130uGydependingonthetrimesterthebabyisin.
The risk increases with each passing week as the surface
area of the fetus increases leading to an enhanced absorption
[32]. Although the fact remains that any radiation exposure
to fetus does carry a risk, it is important that, in an indicated
case, the investigations are performed expeditiously because
theriskoffetaldeathishighinanuntreatedcaseofPE.Apart
fromtheradiationrisktofetus,theriskofradiationexposure
to female breast must also be considered. The female breast
is extremely radiosensitive, and it has been shown that
asuﬃcientlylargeradiationdosecancausebreastcancer[33,
34]. However, as mentioned above, it should not preclude
its use in situations where there is suspicion of PE as the
risks involved in terms of radiation exposure are extremely
smallcomparedtobeneﬁtsoftheearlydiagnosisandprompt
management of PE.
3. Prevention Strategies
3.1. Mechanical Prophylaxis. These measures increase the
venous blood ﬂow in the lower limbs and prevent venous
stasis, an important component of Virchow’s triad [35].
Mechanical prophylaxis includes measures such as physio-
therapy and exercises, use of graduated compression stock-
ings, foot pumps, and intermittent pneumatic compression
devices.
3.2. Physiotherapy and Exercises. All patients should have
a plan for active and passive lower extremity activity unless
contraindicated including ﬂexion and extension of the ankle,
knees, and hips. Involve physical therapy as appropriate.
Provide written instructions, with pictures as well as a dem-
onstration. Early and aggressive ambulation for all patients
if not contraindicated is an important measure to prevent
development of VTE.
3.3. Graduated Compression Stockings (GCSs). Encourage
patients to wear GCSs at all times except when they are
removed for skin care or bathing. Proper size should be
instructed, and it should ideally be thigh high to have eﬀect
on proximal veins. Nursing staﬀ should ensure that stockings
are not leading to a garter eﬀect at the thigh or calf.
3.4. Intermittent Pneumatic Compression (IPC). These
should be used in inactive patients requiring passive
movements. These devices also exert ﬁbrinolytic eﬀect by
stimulating endogenous ﬁbrinolytic mechanism, reducing
plasminogen activator inhibitor activity, and increasing the
levels of tissue plasminogen activator [36].
3.5. IVC Filters. Inferior vena cava ﬁlter placement may
be indicated in high-risk cases where the use of throm-
boprophylaxis is contraindicated due to certain coexisting
morbidities.
3.6. Thromboprophylaxis. Ideally, the evaluation of whether
apatientrequiresthromboprophylaxisshouldbedonebefore
conception or at least early in the pregnancy. Despite a long
list of risk factors for development of VTE, most women do
not require anticoagulation during pregnancy (Table 4).
The risk of complications from anticoagulation, such as
bleeding, can be as high as 2%. Hence, the use of anti-
coagulants is limited to cases where the beneﬁts of its
use are greater than potential adverse eﬀect (Table 5)[ 37–
44]. In general, pregnant women who have had previous
episodesofVTE,thosehavingthrombophiliaespeciallythose
with antithrombin deﬁciency, antiphospholipid syndrome,
compoundheterozygosityforprothrombinG20210Avariant
or factor V Leiden are candidates for thromboprophylaxis.
3.7. Heparin for Thromboprophylaxis. Heparin both unfrac-
tionated and low molecular weight heparin are agents of
choice for thromboprophylaxis during pregnancy. Neither
of them cross placenta making it safe for use in pregnancy.
HeparinbothUFHandLMWHactbybindingtoantithrom-
bin to catalyse the molecule binding to and altering the
activity of serine protease procoagulants thus interrupting
the coagulation pathway [41–44]. UFH enhances the activity
of antithrombin for factor Xa and thrombin, whereas the
predominant eﬀect of LMWH is via antithrombin-mediated
antifactor Xa activity. The dosage and monitoring strategy
for UFH is mentioned in Table 6.
Although there are few direct studies comparing the use
of UFH to LMWH during pregnancy, it is widely agreed that
the use of LMWH is associated with lower incidence of
complications [45, 46]. UFH has complex pharmacokinetics
that potentially leads to a somewhat unpredictable antico-
agulant response. Also, the bioavailability of the UFH after
subcutaneous (SC) injection is reduced compared with in-
travenous infusion. LMWH, in contrast, is less likely to
bind nonspeciﬁcally to various circulating protein or cell
surfacesandsohasimprovedpharmacokineticsandbioavail-
ability when given SC [47–49]. Other potential advantages
include ease of administration, less bleeding, less incidences
of heparin-induced thrombocytopenia (HIT), and a pre-
dictable response although the therapy is relatively more
expensive. Various types of LMWH and their dosage are
mentioned in Table 7. One important aspect that should be
taken care of during the last trimester of pregnancy is to4 Journal of Pregnancy
Table 4: Indications for thromboprophylaxis during pregnancy.
(1) Mechanical heart valve
(2) Rheumatic heart disease
(3) Atrial ﬁbrillation
(4) Antithrombin III deﬁciency
(5) Antiphospholipid syndrome
(6) Prior anticoagulation therapy
(7) Factor V Leiden defect
(8) Prothrombin G20210A mutation
Table 5: Unique aspects that need to be considered for thrombo-
prophylaxis during pregnancy.
(1) Transplacental transfer
(2) Expanded blood volume up to 50%
(3) Increase in volume of distribution
(4) Increase in GFR leading to enhanced excretion of heparin
(5) Enhanced protein binding of heparin
(6) Shorter half lives of UFH and LMWH—higher and frequent
dose requirement
(7) Risk of heparin-induced thrombocytopenia (also known as
HIT)
shift the patients on LMWH to UFH at 36-37 weeks. This
is important to prevent development of epidural hematoma,
in case an epidural analgesia is planned. In cases of planned
caesarean sections, LMWH can be continued even up to
6–12hrs before surgery. UFH on the other hand has short
half life and can be stopped four hours before the epidural
insertion with minimal risks and hence is favored over
LMWH by many obstetricians towards the term.
Another newer oral anticoagulant that is being increas-
ingly used is oral anti-Xa inhibitor Rivaroxaban (Trade
name: Xarleto). However, there are no adequate data of its
use in pregnant women. In fact, studies in animals have
shown reproductive toxicity secondary to trans-placental
transmission. Due to this potential risk, its use is contraindi-
cated in the pregnancy.
3.8. Treatment of VTE Using Heparins in Pregnancy. For
managingVTEduringpregnancy,twoalternativeapproaches
areemployed:(1)IVUFHfollowedbyatleast3monthsofSC
LMWH or adjusted-dose SC UFH or (2) adjusted-dose SC
UFH or LMWH can be used both for initial and long-term
treatment. With UFH, doses should be adjusted to prolong
a midinterval aPTT into the therapeutic range (adjusted-
dose SC heparin). As mentioned above, LMWH is the pre-
ferred agent amongst the two because of various reasons
including better safety proﬁle, ease of administration, and
easier monitoring. Since the half life of LMWH is decreased
inpregnancy,twice-dailyregimensareprobablypreferableto
once-dailydosingandasthepregnancyprogresses(andmost
womengainweight),thepotentialvolumeofdistributionfor
LMWH changes requiring change in the dose and pattern of
administration. Apart from the usual weight-based regime,
Table 6: Thromboprophylaxis using UFH—dosage and monitor-
ing.
(1) Low-dose prophylaxis
(a) First trimester: 5000 to 7000 Units q12hours
(b) Second trimester: 7500 to 10,000 Units q12hours
(c) Third trimester: 10,000 Units q12hours
(i)Unless aPTT elevated
(2) Adjusted dose prophylaxis to aPTT of 1.5 to 2.5
(a) Dose: 10,000 q8–12 hours
(b) Goal aPTT: 1.5 to 2.5 times normal
some clinicians prefer to perform regular antifactor Xa levels
3to4hafterthemorningdoseandadjustthedoseofLMWH
to achieve an anti-Xa level of approximately 0.5 to 1.2U/mL
[50, 51].
3.9. Use of Warfarin in Pregnancy. Since warfarin crosses
placenta, its use is associated with fetal hazards and thus is
not recommended during pregnancy. It is associated with
high risk of miscarriages with reports indicating rates as high
as 56% if taken during ﬁrst trimester. It has also shown
to have 30% risk of congenital anomalies. Warfarin embry-
opathy is characterized by midface hypoplasia, stippled
chondral calciﬁcation, scoliosis, short proximal limbs, and
short phalanges; it aﬀects 5% of fetuses that are exposed to
the drug between 6 and 9 weeks of gestation [52]. The use
of warfarin in the second trimester and early in the third
trimester is associated with fetal intracranial haemorrhage
and schizencephaly [53, 54]. Long-term squeal includes risk
o fa d v e r s en e u r o l o g i c a lo u t c o m ea n du pt o4 %l o w e rI Q .
There are few conditions in which warfarin may be
used preferentially over heparins by certain clinicians. Cer-
tain reports have shown that the LMWH may not be as
eﬀective as warfarin in protecting mothers from thrombosis
of prosthetic valves [55]. Viteale et al. [56] recommend
that patient with prosthetic valves whose warfarin intake is
5mg with an international normalized ratio (INR) within
therapeutic range may continue to take warfarin during
the entire pregnancy under strict medical surveillance and
consideraprogrammedcaesareansectionatthe38thweekof
gestation while brieﬂy interrupting warfarin therapy. On the
other hand, those patients whose warfarin doses are >5mg
should be made fully aware of a likely much higher risk of
fetal complications during pregnancy. If they decide to carry
on pregnancy with warfarin and have a bileaﬂet or aortic
valve prosthesis, the INR range may be lowered to 2.0–2.5
with the aim of bringing the warfarin intake down to 5mg
while still reaching a satisfactory antithrombotic eﬀect. In
those women who choose not to take warfarin and are at
higher thrombotic risk (mitral prostheses, atrial ﬁbrillation,
ﬁrst-generationvalves,andpreviousthromboembolism), in-
hospital heparin treatment, at least between weeks 6 and 12
and 2 weeks before delivery, seems justiﬁed. Warfarin for
thromboprophylaxis during the postpartum period may be
considered where the adverse eﬀect to fetus is not a concern.
Warfarin is not secreted in breast milk and thus can be safely
given during this phase.Journal of Pregnancy 5
Table 7: Dose of LMWH as per body weight.
LMWH type Body weight < 50Kg 50–69Kg 70–90kg >90kg
Enoxaparin 20mg daily 60mg daily 40mg twice daily 40mg twice daily
Dalteparin 5000Udaily 6000U daily 8000U daily 10,000U daily
Tinzaparin 175U/kg once daily 175U/kg once daily 175U/kg once daily 175U/kg once daily
Rivaroxaban (oral) Contra indicated
3.10. Management in Case of Suspicion of VTE. In cases
wheretheVTEissuspected,themanagementdependsonthe
degree of clinical suspicion and the stage of pregnancy. The
management will also change if certain anticoagulants are
contraindicatedandwhetherDVT,PE,orbotharesuspected.
In cases where there is a strong suspicion of an acute episode
of pulmonary embolism, it is advisable to start anticoagulant
therapy even before the diagnostic evaluation. It may be dis-
continued if the diagnostic evaluation refutes the diagnosis.
In cases of low to moderate degree of suspicion of PE, it
is better to evaluate the patient clinically and diagnostically
before the anticoagulant therapy is instituted.
In cases where there is a strong suspicion of PE and anti-
coagulant therapy is contraindicated, a diagnostic evaluation
is warranted without any waste of time. The basic manage-
ment include supportive management and timely delivery
of the fetus. Once the PE is conﬁrmed, other measures
especiallylikeIVCﬁltermaybeneeded.Incaseofconcernfor
isolated DVT without PE, it is better to diagnostically evalu-
ate the patient before anticoagulant therapy is instituted.
4. Conclusion
For patients with risk factors, general thromboprophylaxis,
such as lower extremity exercise on a bed; GCS, Intermittent
Pneumatic compression (IPC), and adequate hydration
postpartum, are recommended. Early ambulation should
be encouraged even after a normal delivery in low-risk
patients. In addition, pharmacologic thromboprophylaxis
with LMWH or warfarin should be considered in patients
with risk factors other than caesarean section. For high-risk
pregnancies with documented thrombophilia such as pos-
itive antiphospholipid antibody or previous VTE, pharma-
cologic thromboprophylaxis with LMWH is recommended.
Warfarin is contraindicated during pregnancy (category X).
However, warfarin can replace LMWH after delivery and be
u s e df o r6w e e k st o3m o n t h sf o rc o n t i n u e dp o s t p a r t u m
thromboprophylaxis.
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